X-linked Severe Combined Immunodeficiency
Conditions
Keywords
X-linked severe combined immunodeficiency, gene therapy, Patients will be enrolled following diagnosis and referral to Great Ormond Street Immunology Service.
Brief summary
X-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.
Interventions
GENETICSingle infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
Sponsors
Great Ormond Street Hospital for Children NHS Foundation Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
No minimum to 16 Years
Healthy volunteers
No
Inclusion criteria
1. No HLA identical (A,B,C,DR,DQ) family donor and no HLA identical unrelated donor available within 3 months of diagnosis or patients whose underlying clinical problems and prognosis would be significantly compromised by chemotherapy conditioning (including persisting pneumonitis, protracted diarrhoea requiring parental nutrition, ongoing visceral viral infection (herpes viruses, HSV,VZV,CMV, EBV or adenovirus), systemic BCG infection, virus-induced lymphoproliferation. 2. Diagnosis of classical SCID-X1 based on immunophenotype (absent, or reduced numbers of non-functional T lymphocytes) and confirmed by DNA sequencing 3. Parental/guardian voluntary consent 4. Boys between the ages of 0 and 16
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunological reconstitution | 1-18 months post-infusion,then annually | * Immunophenotyping: detection of naïve CD3+ T-cell numbers, CD4, CD8, TCRαβ, TCRγδ, CD16+CD56+ NK & gamma chain expression. TRECs may be enumerated as surrogate marker for new thymic emigrants post-gene therapy * Lymphocyte proliferation assays to test function of T cells * Representation of TCR families by flow cytometry (Vβ phenotyping), & CDR3 PCR spectratyping (Vβ spectratyping) to monitor physiological & potentially pathological clonal expansions * Restoration of antibody production (IgA, IgM, IgG) & serological responses to vaccinations & natural infections. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse reactions | from consent until 5 years post-infusion of gene-modified cells | At each scheduled visit, adverse events that might have occurred since the previous visit or assessment will be elicited from the patient/parent/guardian. The investigators will maintain a record of all adverse events/occurrences in patients participating in the clinical trial. This record will be noted in the patient's medical notes. Adverse events that have a causal relationship to the IMP (ARs) and SAEs will be recorded on the AE reporting section of the CRF. |
| Molecular characterisation of gene transfer | until 5 years post-infusion of gene-modified cells | Quantification of transgene copy numbers is determined on sorted cell populations by real-time PCR methodology. Detailed integration analysis may be used to investigate specific clonal expansions. |
| Normalisation of nutritional status, growth, and development | until 5 years post-infusion of gene-modified cells | Normalisation of nutritional status, growth, and development will be assessed at each follow-up visit by the investigator through clinical examinations. |
Countries
United Kingdom
Outcome results
None listed